Bionic P&O Chosen as First Distributor of Ekso Indego® Personal Within the Orthotics & Prosthetics Industry
Ekso Bionics (Nasdaq: EKSO) has announced a non-exclusive distribution agreement with Bionic Prosthetics & Orthotics Group (Bionic P&O) for the Ekso Indego® Personal device, marking the company's first entry into the orthotics & prosthetics industry.
The Ekso Indego Personal is a wearable powered exoskeleton for individuals with spinal cord injuries (SCIs), featuring:
- Modular quick connect design for independent use
- Lightest commercial exoskeleton available
- Advanced gait mode enabling faster walking speeds
- Enhanced independence for users
This strategic alliance aims to leverage Bionic P&O's expertise in market dynamics, reimbursement landscape, and patient needs to effectively distribute the innovative device within the O&P community.
Ekso Bionics (Nasdaq: EKSO) ha annunciato un accordo di distribuzione non esclusivo con Bionic Prosthetics & Orthotics Group (Bionic P&O) per il dispositivo Ekso Indego® Personal, segnando il primo ingresso dell'azienda nel settore delle ortesi e protesi.
L'Ekso Indego Personal è un esoscheletro indossabile e motorizzato per persone con lesioni del midollo spinale (SCI), caratterizzato da:
- Design modulare con connessione rapida per l'uso indipendente
- Esoscheletro commerciale più leggero disponibile
- Modalità di camminata avanzata che consente velocità maggiori
- Maggiore autonomia per gli utenti
Questa alleanza strategica punta a sfruttare l'esperienza di Bionic P&O nel comprendere le dinamiche di mercato, il sistema di rimborso e le esigenze dei pazienti per distribuire efficacemente il dispositivo innovativo nella comunità delle ortesi e protesi.
Ekso Bionics (Nasdaq: EKSO) ha anunciado un acuerdo de distribución no exclusivo con Bionic Prosthetics & Orthotics Group (Bionic P&O) para el dispositivo Ekso Indego® Personal, marcando la primera incursión de la compañía en la industria de ortesis y prótesis.
El Ekso Indego Personal es un exoesqueleto portátil motorizado para personas con lesiones de la médula espinal (SCI), que cuenta con:
- Diseño modular de conexión rápida para uso independiente
- El exoesqueleto comercial más ligero disponible
- Modo de marcha avanzado que permite velocidades de caminata más rápidas
- Mayor independencia para los usuarios
Esta alianza estratégica busca aprovechar la experiencia de Bionic P&O en dinámicas de mercado, sistemas de reembolso y necesidades de los pacientes para distribuir eficazmente el innovador dispositivo dentro de la comunidad de ortesis y prótesis.
Ekso Bionics(나스닥: EKSO)는 Bionic Prosthetics & Orthotics Group(Bionic P&O)과 Ekso Indego® Personal 장치에 대한 비독점 배급 계약을 체결했다고 발표했으며, 이는 회사가 보조기구 및 의수족 산업에 처음 진출하는 것입니다.
Ekso Indego Personal은 척수 손상(SCI) 환자를 위한 착용형 동력 외골격으로, 다음과 같은 특징이 있습니다:
- 독립 사용이 가능한 모듈식 빠른 연결 디자인
- 가장 가벼운 상용 외골격
- 더 빠른 보행 속도를 가능하게 하는 고급 보행 모드
- 사용자의 독립성 향상
이번 전략적 제휴는 Bionic P&O의 시장 동향, 보험 환급 체계, 환자 요구에 대한 전문성을 활용하여 보조기구 및 의수족 커뮤니티 내에서 혁신적인 장치를 효과적으로 배포하는 것을 목표로 합니다.
Ekso Bionics (Nasdaq : EKSO) a annoncé un accord de distribution non exclusif avec Bionic Prosthetics & Orthotics Group (Bionic P&O) pour le dispositif Ekso Indego® Personal, marquant la première entrée de la société dans le secteur des orthèses et prothèses.
L'Ekso Indego Personal est un exosquelette motorisé portable destiné aux personnes souffrant de lésions de la moelle épinière (SCI), doté de :
- Un design modulaire à connexion rapide pour une utilisation autonome
- L’exosquelette commercial le plus léger disponible
- Un mode de marche avancé permettant des vitesses de déplacement plus rapides
- Une plus grande autonomie pour les utilisateurs
Cette alliance stratégique vise à tirer parti de l’expertise de Bionic P&O en matière de dynamique de marché, de remboursement et des besoins des patients afin de distribuer efficacement ce dispositif innovant au sein de la communauté des orthèses et prothèses.
Ekso Bionics (Nasdaq: EKSO) hat eine nicht-exklusive Vertriebsvereinbarung mit Bionic Prosthetics & Orthotics Group (Bionic P&O) für das Ekso Indego® Personal Gerät bekannt gegeben, was den ersten Einstieg des Unternehmens in die Orthesen- und Prothetikbranche markiert.
Das Ekso Indego Personal ist ein tragbares, motorisiertes Exoskelett für Personen mit Rückenmarksverletzungen (SCI) und verfügt über:
- Modulares Schnellverbindungssystem für unabhängige Nutzung
- Leichtestes kommerzielles Exoskelett auf dem Markt
- Fortschrittlichen Gehmodus für schnellere Gehgeschwindigkeiten
- Erhöhte Unabhängigkeit für die Anwender
Diese strategische Partnerschaft zielt darauf ab, die Expertise von Bionic P&O bezüglich Marktdynamik, Erstattungssystemen und Patientenbedürfnissen zu nutzen, um das innovative Gerät effektiv in der O&P-Community zu vertreiben.
- First entry into orthotics & prosthetics market, expanding distribution channels
- Partnership with established national provider enhances market access
- Product differentiation with lightest commercial exoskeleton and unique features
- Non-exclusive distribution agreement limits market control
- Success dependent on distributor's performance and market acceptance
Insights
Ekso's new O&P distribution partnership with Bionic P&O creates a strategic channel to reach spinal cord injury patients through specialized providers.
This distribution agreement marks Ekso Bionics' first entrance into the orthotics and prosthetics (O&P) industry, creating a new commercial channel for their Ekso Indego Personal device targeting patients with spinal cord injuries. The partnership gives Ekso access to specialized distribution knowledge essential for navigating the complex O&P market.
The non-exclusive nature of this agreement suggests Ekso may pursue additional O&P distributors as part of a broader market penetration strategy, while still leveraging Bionic P&O's expertise. The company is strategically positioning its product by highlighting several competitive advantages:
- Modular quick connect design allowing users to operate independently
- Described as the lightest known commercial exoskeleton available
- Advanced gait mode technology that enables faster walking speeds
This partnership addresses a critical commercialization challenge for medical device companies - establishing effective distribution channels with partners who understand specific market dynamics and reimbursement landscapes. By partnering with an established O&P provider, Ekso gains access to clinical networks already serving spinal cord injury patients.
While this agreement represents a positive strategic development in expanding market access, the announcement lacks financial details or specific sales targets, making it difficult to quantify the immediate revenue impact. The medical device distribution process typically involves significant education and training components, suggesting gradual rather than immediate market penetration.
This distribution agreement reflects an intelligent channel expansion strategy by Ekso Bionics. The O&P industry represents a logical but previously untapped market for their exoskeleton technology, as these providers already serve patients with mobility limitations.
Partnering with Bionic P&O, described as a "leading national provider" in the space, gives Ekso access to established clinical relationships and specialized knowledge. The comments from both CEOs emphasize the alignment in patient-centered mission between the companies, which typically correlates with successful partnership outcomes in healthcare.
The exoskeleton market faces two primary challenges: technology accessibility and reimbursement complexity. This partnership appears designed to address both issues by leveraging Bionic P&O's expertise in what CEO Scott Davis specifically calls "the reimbursement landscape." O&P providers have deep experience navigating insurance coverage for mobility devices.
Strategically, entering the O&P channel diversifies Ekso's commercialization approach beyond direct sales or hospital-focused distribution. The non-exclusive structure provides flexibility to expand with additional O&P partnerships if this initial collaboration proves successful.
While the announcement offers no financial projections or deal terms, the specialization of powered exoskeleton technology suggests this represents a targeted rather than mass-market opportunity. The emphasis on the device's technical advantages (modular design, lightweight construction, advanced gait capabilities) indicates Ekso is positioning for competitive differentiation within the specialized exoskeleton segment.
Alliance marks Ekso Bionics’ first entrance into the O&P space
SAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named Bionic Prosthetics & Orthotics Group LLC (“Bionic P&O”), a leading national provider of prosthetic and orthotic solutions, as a non-exclusive Ekso Indego® Personal device distributor.
Ekso Indego Personal is a wearable lower extremity powered exoskeleton that enables certain individuals living with spinal cord injuries (“SCIs”) with the ability to stand and walk independently. It is the only known portable exoskeleton device to offer a modular quick connect design, which was engineered to allow users to put on and take off the device without assistance. Ekso Indego Personal is the lightest known commercial exoskeleton available offering ease of handling, transportation, and storage. Also offering an advanced gait mode, individuals with a SCI using the device have been shown to reach faster walking speeds, granting them a new level of independence in the community.
“This exciting new commercial alliance with a recognized leader like Bionic P&O aligns squarely with our mission of improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function,” commented Scott Davis, the Company’s Chief Executive Officer. “From a business perspective, the successful marketing and distribution of an innovative device like Ekso Indego Personal requires deep insight into the particular market dynamics, the reimbursement landscape, and above all, the needs of patients served within the community. I cannot think of a better choice than Bionic P&O as our first distributor for Ekso Indego Personal within the important orthotics and prosthetics industry.”
“True innovation that supports patients in reaching their goals, paired with compassionate care, is the cornerstone of Bionic P&O’s success. Bionic P&O’s mission is to empower individuals to live more independent and fulfilling lives. We believe the Ekso Indego Personal device will make a lasting positive impact on our patients’ lives and has the potential to transform the orthotics and prosthetics industry,” said Daniel Chan, National Business Development Manager at Bionic P&O. “We are thrilled by our alliance with Ekso Bionics. Together, we are paving the way for a future where spinal cord injury patients can not only dream of walking again, but actively work towards that goal.”
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com.
About Bionic P&O
Founded in 2007, Bionic P&O is an independent clinical practice group that now operates across 12 states: Florida, Illinois, Indiana, Kentucky, Michigan, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, and Wisconsin. Fully accredited by the American Board for Certification in Orthotics, Prosthetics, and Pedorthics (ABC), Bionic P&O employs certified/licensed O&P practitioners with expertise in a wide range of specialties, including advanced lower and upper limb prosthetics, lower and upper limb orthotics, spinal orthotics, pediatric orthotics, and cranial remolding orthotics. For more information, visit: www.bionicpo.com.
Forward-Looking Statements
Any statement contained in this press release that does not describe historical facts may constitute a forward-looking statement. Forward-looking statements may include, without limitation, statements regarding the ability of Bionic P&O to distribute the Company’s Ekso Indego Personal device within the orthotics and prosthetics products industry in the United States, the impact to the Company and the broader industry of the Company’s partnership with Bionic P&O, the potential impacts of the Company’s device to patients using the device, and the Company’s ability to bolster demand for its technology and execute on its long-term growth strategy. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund and grow the Company's operations and to develop or enhance the Company’s technology, the Company’s inability to obtain future reimbursements from CMS in a timely manner and at the expected reimbursement levels, the Company’s inability to obtain insurance coverage beyond CMS, the Company’s inability to obtain additional indications of use for its devices, any delay or discontinuation of the sales and distribution of Esko Indego Personal within the orthotics and prosthetics products industry, or Ekso Indego Personal risks related to product liability, recall and warranty claims. These and other factors are identified and described in more detail in the Company’s filings with the U.S. Securities and Exchange Commission. To learn more about Ekso Bionics please visit the Company’s website at www.eksobionics.com or follow @EksoBionics on X. The Company does not undertake to update these forward-looking statements, except as required by law.
Contact:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@eksobionics.com
FAQ
What features make the Ekso Indego Personal unique in the exoskeleton market?
How will the distribution agreement with Bionic P&O impact EKSO's market presence?
What medical conditions can benefit from the Ekso Indego Personal device?
What are the key advantages of EKSO's partnership with Bionic P&O?
